Effects of PAF Antagonist, BN52021, on the PAF-, Methacholine-, and Allergen-Induced Bronchoconstriction in Asthmatic Children

  • Kue-Hsiung Hsieh
    Reprint requests: Dr. Hsieh, Department of Pediatrics, National Taiwan University Hospital, Kaohsiung, Taiwan, ROC
    From the Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan, Republic of China
    Search for articles by this author
      Platelet-activating factor (PAF) is an inflammatory mediator capable of inducing protracted inflammation of the airways and bronchial hyperreactivity. Twenty-one asthmatic children were evenly divided into three groups and each group performed a double-blind, placebo-controlled and crossover study on the effect of aerosolized BN52021, a PAF antagonist, on the bronchoconstriction induced by PAF, methacholine, or specific allergen, respectively. One group of healthy children was included for comparison. Total WBC, neutrophils, and eosinophils were counted before and after PAF challenge. The results showed the following: (1) six of seven asthmatics and one of seven normal subjects gave a positive bronchial provocation with PAF; (2) in asthmatics, prior inhalation of BN52021 could inhibit the bronchoconstriction induced by PAF (6/6) and allergen (3/7), but not by methacholine; and (3) 5 min after inhalation of PAF, there was a marked decrease of peripheral blood eosinophils and neutrophils that could be inhibited by prior inhalation of BN52021 in normal subjects but not in asthmatics. These findings support the idea that PAF may be involved in the pathogenesis of bronchial asthma and PAF antagonist may have a role in the prevention and treatment of this disease.
      To read this article in full you will need to make a payment


      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Benveniste J
        • Henson PM
        • Cochrane CG
        Leukocyte-dependent histamine release from rabbit platelet: the role of IgE, basophils, and a platelet-activating factor.
        J Exp Med. 1972; 136: 1365-1376
        • Braquet P
        • Touqui L
        • Shen TY
        • Vargaftig BB
        Prospectives in platelet activating factor research.
        Pharmacol Rev. 1987; 39: 97-145
        • Vargaftig BB
        • Lefort J
        • Chignard M
        • Benveniste J
        Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives.
        Eur J Pharmacol. 1980; 65: 185-192
        • Pinckard RN
        • McManus LM
        • Halonen M
        • Hanahan D
        Immunopharmacology of acetyl glyceryl ether phosphorylcholine (AGEPC).
        in: Newball HH Immunopharmacology of the lung. Marcel Dekker, New York1984: 73-103
        • Fabbri L
        Airway inflammation and asthma: importance of arachidonate metabolites for airway hyperresponsiveness.
        Prog Biochem Pharmacol. 1985; 20: 18-25
        • Mazzoni L
        • Morley J
        • Page CP
        • Sanjar S
        Induction of airway hyper-reactivity by platelet activating factor in the guinea-pig.
        J Physiol. 1983; 365: 107
        • Aoki S
        • Boubekeur K
        • Burrows L
        • Morley J
        • Sanjar S
        Recruitment of eosinophils by platelet activating factor (PAF) in the guinea pig lung.
        J Physiol. 1987; 394: 130
        • Stevenson JS
        • Tallent M
        • Blinder B
        • Abraham WM
        Modification of antigen-induced late responses with an antagonist of platelet-activating factor (WEB 2086).
        Fed Proc. 1987; 46: 1454A
        • Coyle AJ
        • Sjoerdsma K
        • Page CP
        • Brown L
        • Metzger WJ
        Modification of the late-phase asthmatic response and bronchial hyperreactivity by BN52021, a platelet-activating factor antagonist.
        Clin Res. 1987; 35: 254A
        • Knauer KA
        • Lichtenstein LM
        • Franklin Jr, Adkinson N
        • Fish JE
        Platelet activation during antigen-induced airway reactions in asthmatic subjects.
        N Engl J Med. 1981; 304: 1404-1407
        • Metzger WJ
        • Hunninghake GW
        • Richerson HB
        Late asthmatic responses: inquiry into mechanisms and significance.
        Clin Rev Allergy. 1985; 3: 145-165
        • Grandel KE
        • Wardlow ML
        • Fare RS
        Platelet activating factor in sputum of patients with asthma and COPD.
        Fed Proc. 1985; 44: 184
        • Gateau O
        • Arnoux B
        • Deriaz H
        • Viars P
        • Benveniste J
        Acute effects of intratracheal administration of PAF-acether (platelet-activating factor) in humans.
        Am Rev Respir Dis. 1984; 129: A3
        • Cuss FM
        • Dixon CMS
        • Barbes PJ
        Effect of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man.
        Lancet. 1986; 2: 189-192
        • Rubin AHE
        • Smith LJ
        • Patterson R
        The bronchoconstrictor properties of platelet-activating factor in humans.
        Am Rev Respir Dis. 1987; 136: 1145-1151
        • Touvay C
        • Etieune A
        • Braquet P
        Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN52021, a new specific PAF-acether receptor antagonist isolated from Ginkgo biloba.
        Agent Act. 1986; 17: 371-372
        • Hsieh KH
        Forced vital capacity and one-second forced expiratory volume in 1,462 normal children.
        Acta Paediatr Sin. 1974; 15: 166-171
        • Chai H
        • Farr RS
        • Frochlich LA
        • Mathison DA
        • McLean JA
        • Rosenthol RR
        • et al.
        Standardization of bronchial inhalation challenge procedures.
        J Allergy Clin Immunol. 1975; 56: 323-327
        • Rosenthal RR
        Inhalation challenge.
        in: Melillo GH Norman PS Marone G Respiratory allergy, clinical immunology. BC Decker Inc, Philadelphia1990: 2171-2177
        • Miwa M
        • Kiyake T
        • Yamanaka T
        • et al.
        Characterization of serum platelet-activating factor acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.
        J Clin Invest. 1988; 82: 1983-1991
        • Stimler NP
        • Bloor CM
        • Hugli TE
        • Wykle RL
        • McCall CE
        • O'Flaherty JT
        Anaphylactic actions of platelet-activating factor.
        Am J Pathol. 1981; 105: 64-69
        • Halonen M
        Differential effects of platelet depletion on the physiologic alterations of IgE anaphylaxis and acetyl ether phosphorylcholine infusion in the rabbit.
        Am Rev Respir Dis. 1981; 124: 416-421
        • Chung KF
        • Barnes PJ
        Bronchial hyperreactivity induced by platelet-activating factor (PAF): modification by a beta-agonist.
        Thorax. 1987; 42: 220-226
        • Holonen M
        • Lohman IC
        • Dunn AM
        • McManus KM
        • Palmer JD
        Participation of platelets in the physiologic alterations of the AGEPC response and of IgE anaphylaxis in the rabbit.
        Am Rev Respir Dis. 1985; 131: 11-17
        • Dewar A
        • Archer CB
        • Paul W
        • Page CP
        • MacDonald DM
        • Morley J
        Cutaneous and pulmonary histopathological responses to platelet activating factor (PAF-acether) in the guinea-pig.
        J Pathol. 1984; 144: 24-34
        • Morley J
        • Page CP
        • Sanjar S
        The platelet in asthma.
        Lancet. 1984; 2: 1142-1144
        • Arnoux B
        • Simoes-Caeioro MH
        • Landes A
        • Mathieu M
        • Duroux P
        • Benveniste J
        Alveolar macrophages from asthmatics release PAF-acether and lyso-PAF-acether when stimulated with specific antigen.
        Am Rev Respir Dis. 1982; 125: 70
        • Guinot P
        • Braquet P
        • Duchier J
        • Cournoot A
        Inhibition of PAF-acether induced weal and flare reaction in man by a specific PAF antagonist.
        Prostaglandins. 1986; 32: 160-163
        • Chung KF
        • McCusker M
        • Page CP
        • Dent G
        • Guuinot P
        • Barnes PJ
        Effect of ginkgolide mixture (BN52063) in antagonizing skin and platelet responses to platelet activating factor in man.
        Lancet. 1987; 1: 248-251
        • Roberts NM
        • Page CP
        • Chung KF
        • Barnes PJ
        Effect of a PAF antagonist, BN52063, on antigen-induced, acute and late-onset cutaneous responses in atopic subjects.
        J Allergy Clin Immunol. 1988; 82: 236-241
        • Guinot P
        • Brambiilla C
        • Duchieer J
        • Braquet P
        • Bon voisin B
        • Courot A
        Effect of BN52063, a specific PAF-acether antagonist, on bronchial provocation to allergens in asthmatic patients: a preliminary study.
        Prostaglandins. 1987; 34: 723-731
        • Chung KF
        • Dent G
        • Barnes PJ
        Effects of salbutamal on bronchoconstriction, bronchial hyperresponsiveness, and leukocyte responses induced by platelet activating factor in man.
        Thorax. 1989; 44: 102-107
        • Chung KF
        • Aizawa HA
        • Leikavf GD
        • Ueki IF
        • Evans TW
        • Nadel JA
        Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane-A2.
        J Pharmacol Exp Ther. 1986; 236: 580-584
        • Mandi Y
        • Farkas G
        • Koltai M
        • Braquet P
        • Beladi I
        The effect of BN52021, a PAF-acether antagonist, on natural killer activity.
        in: Braquet P Platelet-activating factor and cellular immunology. Karger, Basel1988: 76-84